Article Text

Download PDFPDF
Publishing the evidence for children’s medicines
  1. Imti Choonara1,
  2. Howard Bauchner2
  1. 1
    Academic Division of Child Health, University of Nottingham, Derbyshire Children's Hospital, Derby, UK
  2. 2
    Boston University School of Medicine, Boston, MA, USA
  1. Imti Choonara, Academic Division of Child Health, University of Nottingham, Derbyshire Children’s Hospital, Derby DE22 3DT, UK; imti.choonara{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The right of children to receive medicines that have been scientifically tested for both efficacy and safety is now becoming widely accepted. Tragedies such as the grey baby syndrome in association with the use of the antibiotic chloramphenicol in neonates could have been avoided if appropriate scientific studies had been performed.1 European legislation has now established that children should have the same rights as adults to receive medicines that have been proven to be of benefit and are unlikely to cause serious toxicity.2 The European legislation follows on from American initiatives and should result in improved drug therapy for children. National networks to coordinate clinical trials of medicines in children have been established in several European countries alongside North American …

View Full Text


  • Competing interests: None.